Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $25.60.

ATXS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer boosted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Astria Therapeutics by 152.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after purchasing an additional 189,727 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Astria Therapeutics in the third quarter valued at about $613,000. FMR LLC boosted its stake in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares during the period. Vestal Point Capital LP increased its position in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the last quarter. Finally, Sofinnova Investments Inc. purchased a new stake in shares of Astria Therapeutics in the 2nd quarter valued at approximately $552,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Trading Up 0.2 %

ATXS stock opened at $9.54 on Thursday. Astria Therapeutics has a 12-month low of $6.58 and a 12-month high of $16.90. The business’s 50-day moving average is $10.54 and its 200 day moving average is $10.72. The stock has a market cap of $538.38 million, a price-to-earnings ratio of -4.56 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.